Efficacy and Safety of Adeno-Associated Virus-Based Clinical Gene Therapy for Hemophilia: A Systematic Review and Meta-Analysis
Human Gene Therapy · 2024-02 · 35 (3-4) · 93-103
DOI: 10.1089/hum.2023.208 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Human Gene Therapy, online erschienen am 15.02.2024. Verfasst von Zeyu Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Hemophilia A, Hemophilia B. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Clinical trials of adeno-associated virus (AAV)-based gene therapy have made remarkable progress in recent years. We aimed to perform a systematic review and meta-analysis of the literature to assess the efficacy and safety of AAV-based gene therapy for hemophilia. We systematically searched the Web of Science, Embase, PubMed, and the Cochrane Database of Systematic Reviews databases, for clinical trials involving patients diagnosed with hemophilia and treated with AAV-mediated gene therapy. Data on the annualized bleeding rate (ABR), annualized infusion rate (AIR), the incidence of treatment-related adverse events (TRAEs), severe adverse events (SAEs), and alanine aminotransferase (ALT) elevation were extracted as our outcomes. A total of 12 articles from 11 clinical trials were selected from 868 articles for meta-analysis. Pooled analyses showed that AAV-based gene therapy in hemophilia patients reduced the number of bleeding events and the number of factor infusion events by an approximate average of 7 per year and 103 per year, respectively. Eighty percent, 18%, and 63% of hemophilia patients had elevated TRAE, SAE, and ALT levels, respectively. Moreover, subgroup analysis found a significant reduction in ABR and AIR 2–3 years after the therapy. Additional findings that were not pooled including coagulation factor activity are presented in the accompanying tables. Our analysis supported the efficacy and safety of AAV-mediated gene therapy for hemophilia, providing evidence for its application as a therapeutic option for widespread clinical use in hemophilia patients in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
- Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
ORCID-Profile: Jianzhong Ai
Zitieren
APA
Han, Z., Yi, X., Li, J., Liao, D., Gao, G., & Ai, J. (2024). Efficacy and Safety of Adeno-Associated Virus-Based Clinical Gene Therapy for Hemophilia: A Systematic Review and Meta-Analysis. Human Gene Therapy, 35(3-4), 93-103. https://doi.org/10.1089/hum.2023.208
Vancouver
Han Z, Yi X, Li J, Liao D, Gao G, Ai J. Efficacy and Safety of Adeno-Associated Virus-Based Clinical Gene Therapy for Hemophilia: A Systematic Review and Meta-Analysis. Human Gene Therapy. 2024;35(3-4):93-103. doi:10.1089/hum.2023.208
BibTeX
@article{Han2024,
author = {Han, Zeyu and Yi, Xianyanling and Li, Jin and Liao, Dazhou and Gao, Guangping and Ai, Jianzhong},
title = {Efficacy and Safety of Adeno-Associated Virus-Based Clinical Gene Therapy for Hemophilia: A Systematic Review and Meta-Analysis},
journal = {Human Gene Therapy},
year = {2024},
volume = {35},
number = {3-4},
pages = {93--103},
doi = {10.1089/hum.2023.208}
}
EUVIMED